TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32067367

Group type: EXPERIMENTAL
Intervention: Broad-spectrum AMPA reactivity (6–8 reactivities)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Moderate AMPA reactivity (3–5 reactivities)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Narrow AMPA reactivity (1–2 reactivities)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Progressors to RA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Broad AMPA reactivity
Number of subjects: 75

Group type: COMPARATOR
Intervention: Medium AMPA reactivity
Number of subjects: 75

Group type: COMPARATOR
Intervention: Narrow AMPA reactivity
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High number of cortical microchannels
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low number of cortical microchannels
Number of subjects: 75
Study: 33314384

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidomain FINGER concept
Number of subjects: 0
Study: 32955023

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination therapy (Acetaminophen + Ibuprofen)
Number of subjects: 154
Study: 34010531

Group type: EXPERIMENTAL
Intervention: Intensive treatment target (systolic blood pressure <120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment target (systolic blood pressure <140 mm Hg)
Number of subjects: 9361
Study: 32621071

Group type: EXPERIMENTAL
Intervention: 1064 mg q8wk
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 882 mg q6wk
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 441 mg q4wk
Number of subjects: 104
Study: 35017008

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150mg daily
Number of subjects: 3103

Group type: COMPARATOR
Intervention: LHRHa
Number of subjects: 3103
Study: 33345567

Group type: EXPERIMENTAL
Intervention: 3-month DAPT
Number of subjects: 972

Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: 3-month DAPT with Orsiro stents
Number of subjects: 972

Group type: COMPARATOR
Intervention: 3-month DAPT with everolimus-eluting stents
Number of subjects: 972
Study: 36371125

Group type: EXPERIMENTAL
Intervention: Restorative Practices (RP) Project schools
Number of subjects: 5878

Group type: COMPARATOR
Intervention: Comparison schools
Number of subjects: 5878
Study: 35062874

Group type: EXPERIMENTAL
Intervention: VAC-optimized group (n = 41)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care group (n = 42)
Number of subjects: 83
Study: 33512329

Group type: EXPERIMENTAL
Intervention: Therapist-guided, VR-based cognitive training intervention combined with treatment as usual
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual without cognitive training
Number of subjects: 36
Study: 34952187

Group type: EXPERIMENTAL
Intervention: Knotted suture anchors
Number of subjects: 64

Group type: COMPARATOR
Intervention: Knotless suture anchors
Number of subjects: 64
Study: 36228297

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered during the induction of anesthesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (CG) without tranexamic acid
Number of subjects: 61
Study: 33992509

Group type: EXPERIMENTAL
Intervention: Lactate threshold (LT) jogging for 2 min
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Onset of blood lactate accumulation (OBLA) jogging for 75 s
Number of subjects: 9

Group type: COMPARATOR
Intervention: 60% Lactate threshold jogging for 200 s
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: OBLA jogging for 75 s
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LT jogging for 2 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: 60% LT jogging for 200 s
Number of subjects: 9
Study: 32513164

Group type: EXPERIMENTAL
Intervention: Mobile phone-based health intervention (including mobile phone reminders and 24/7 call center)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no mobile phone-based health intervention)
Number of subjects: 320
Study: 35366499

Group type: COMPARATOR
Intervention: Standard revascularization procedures with SFA stenting
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Superficial femoral artery stenting supplemented with fasciotomy in the Hunter's canal
Number of subjects: 70
Study: 34777200

Group type: EXPERIMENTAL
Intervention: Tai Chi exercises
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 180
Study: 36306151

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All treatments (Liraglutide, Diet, Sitagliptin)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: GLP-1R antagonism with exendin (9-39)
Number of subjects: 88
Study: 34325333

Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Acute Stenting (AS)
Number of subjects: 112
Study: 32487092

Group type: EXPERIMENTAL
Intervention: Knowledge of danger signs during childbirth
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Knowledge of danger signs during postpartum
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Factors associated with knowledge of danger signs during postpartum
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Factors associated with knowledge of danger signs during childbirth
Number of subjects: 732
Study: 36506904

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM) 1000 mg IV as a single dose
Number of subjects: 362

Group type: COMPARATOR
Intervention: Ferrous Sulphate (FS) tablets 120 mg iron daily, taken twice daily
Number of subjects: 362
Study: 32379837

Group type: EXPERIMENTAL
Intervention: Modified retinal photoplethysmography with simultaneous ophthalmodynamometry
Number of subjects: 16
Study: 32443008

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15% (treated eyes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (untreated eyes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium hyaluronate (control eyes)
Number of subjects: 0
Study: 32149716

Group type: EXPERIMENTAL
Intervention: Smart‐T2 app
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: QuitGuide app
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study: 33727261

Group type: EXPERIMENTAL
Intervention: ER-positive DCIS with distinct ER-negative clones
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: ER-negative DCIS (clonal)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: ER expression
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: PgR status
Number of subjects: 755
Study: 33435881

Group type: EXPERIMENTAL
Intervention: Unplanned reintubation due to AAC
Number of subjects: 123068
Study: 32414956

Group type: EXPERIMENTAL
Intervention: Infections
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Acute upper respiratory tract infection
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Influenza and pneumonia
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Unspecified infections
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Skin infections
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Gastrointestinal infections
Number of subjects: 1005
Study: 32506827

Group type: COMPARATOR
Intervention: TD-0714 (50-600 mg single ascending dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TD-0714 (10-200 mg q.d. for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TD-0714
Number of subjects: 0
Study: 34727008

Group type: EXPERIMENTAL
Intervention: Post-exercise sauna bathing (89 ± 3°C, 10 ± 2% RH)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Endurance training alone (without sauna)
Number of subjects: 13
Study: 33865779

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography assessments of coronary plaque
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Low‐attenuation plaque burden
Number of subjects: 1769
Study: 32319673

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 42
Study: 36064466

Group type: EXPERIMENTAL
Intervention: Online self-directed intervention combining Community Reinforcement Approach and Family Training (CRAFT) with parenting training program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Written psychoeducational material (active control group)
Number of subjects: 76
Study: 32341063

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable Mendelian Randomization (MVMR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 0
Study: 35991052

Group type: EXPERIMENTAL
Intervention: mHealth-based supervised exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: mHealth-based self-directed exercise
Number of subjects: 0
Study: 33008634

Group type: EXPERIMENTAL
Intervention: CMGvent (custom-made mouthguard with respiratory channels)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: nCMG (normal custom-made mouthguard without respiratory channels)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no mouthguard)
Number of subjects: 15
Study: 33773361

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) 2-mA intensity for 20 minutes over 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study: 36038614

Group type: EXPERIMENTAL
Intervention: Experimental videos reviewing preparation and administration of medications used during ovarian stimulation
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo control videos focused on an orientation to IVF
Number of subjects: 368
Study: 33666378

Group type: EXPERIMENTAL
Intervention: docetaxel plus curcumin (6 g/d for 7 days every 3 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: docetaxel plus placebo
Number of subjects: 50
Study: 37399894

Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg orally) plus abiraterone acetate (AAP) (1000 mg/10 mg orally)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg orally) plus AAP (1000 mg/10 mg orally)
Number of subjects: 212
Study: 32865858

Group type: EXPERIMENTAL
Intervention: 755-nm picosecond laser with diffractive lens array (DLA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 755-nm picosecond laser without diffractive lens array (flat optics)
Number of subjects: 18
Study: 32949382

Group type: EXPERIMENTAL
Intervention: Practical Body Image therapy (PBI) with mirror exposure (ME) as an adjuvant to treatment as usual (TAU)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mirror exposure (ME) component of PBI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study: 35347564

Group type: EXPERIMENTAL
Intervention: Accelerometer-based navigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional guidance
Number of subjects: 60
Study: 37449048

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34425851

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 68
Study: 33017433

Group type: EXPERIMENTAL
Intervention: Chronic inflammation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low plasma zinc
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Plasma iron, AGP, TfR, hepcidin, plasma zinc
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MUAC and level of education
Number of subjects: 150
Study: 35218626

Group type: EXPERIMENTAL
Intervention: Acupuncture at Huatuo Jiaji (EX-B2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Core muscle training
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of acupuncture and core muscle training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 33320400

Group type: EXPERIMENTAL
Intervention: Modified cold-atmospheric pressure plasma (MCAP) with surgical mechanical debridement (MD)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Surgical mechanical debridement (MD) with 2% CHX irrigation
Number of subjects: 2
Study: 36432599

Group type: EXPERIMENTAL
Intervention: Oxxynea® (450 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 35493386

Group type: EXPERIMENTAL
Intervention: Tailored workplace intervention developed using the Behavior Change Wheel and APEASE criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored workplace intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32886178

Group type: EXPERIMENTAL
Intervention: Intranasal remimazolam (10, 20, and 40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal remimazolam solution (higher doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal remimazolam (10 to 40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal remimazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous remimazolam (4 mg)
Number of subjects: 0
Study: 616877161

Group type: EXPERIMENTAL
Intervention: VPA + memantine (5 mg/day)
Number of subjects: 191

Group type: COMPARATOR
Intervention: VPA + placebo
Number of subjects: 191
Study: 36227893

Group type: EXPERIMENTAL
Intervention: Group 1 (HCV associated GN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Group 2 (HCV without GN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Group 3 (Healthy HCV negative volunteers)
Number of subjects: 78
Study: 34692442

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32885440

Group type: EXPERIMENTAL
Intervention: Probiotic capsule + placebo of prebiotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oligofructose + placebo of probiotic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo of probiotic + placebo of prebiotic
Number of subjects: 0
Study: 35037883

Group type: EXPERIMENTAL
Intervention: The-Optimal-Lymph flow (TOLF) intervention group
Number of subjects: 120
Study: 32905893

Group type: EXPERIMENTAL
Intervention: On-line, supervised and home-based tele-rehabilitation
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standardised, outpatient pulmonary rehabilitation
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study: 33609100

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 20138
Study: 36334119

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis Probio‐M8, calcium, calcitriol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, calcium, calcitriol
Number of subjects: 40
Study: 34280892

Group type: EXPERIMENTAL
Intervention: Iso-osmolar contrast media (IOCM)
Number of subjects: 15777

Group type: COMPARATOR
Intervention: Low-osmolar contrast media (LOCM)
Number of subjects: 15777
Study: 35758855

Group type: EXPERIMENTAL
Intervention: Roselle drink (200 ml)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo-control drink
Number of subjects: 39
Study: 34628739

Group type: EXPERIMENTAL
Intervention: Deep needling at Zhongwan (CV 12), Tianshu (ST 25), and Liangmen (ST 21) for 60-70 mm, retained for 30 min, once a day, 6 times a week for 2 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional needling depth at the same acupoints for 25 mm, retained for 30 min, once a day, 6 times a week for 2 weeks
Number of subjects: 120
Study: 32829745

Group type: EXPERIMENTAL
Intervention: Face masks for a 30-day period during the pandemic.
Number of subjects: 6000

Group type: COMPARATOR
Intervention: No face masks for a 30-day period during the pandemic.
Number of subjects: 6000
Study: 34121642

Group type: EXPERIMENTAL
Intervention: Icelandic yogurt (IR; n 15, 18 g of protein)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iso-energetic placebo (PR; n 15, 0 g protein)
Number of subjects: 30
Study: 34242614

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiation
Number of subjects: 0
Study: 34378852

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 34196811

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotides (ASO) or small interfering RNA (siRNA) against apolipoprotein(a)
Number of subjects: 0
Study: 33564854

Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 1209
Study: 32066607

Group type: EXPERIMENTAL
Intervention: OHP (Optimal Health Programme) plus treatment as usual
Number of subjects: 156
Study: 35577874

Group type: EXPERIMENTAL
Intervention: Virtual Reality based Exergaming (EG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Exercise Therapy (ET)
Number of subjects: 23
Study: 34151805

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1260
Study: 33142545

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) supplementation at 0.1, 0.2, 0.3, or 0.4 mg/kg
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) supplementation
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Basal diet or SY-supplemented diet
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Sodium selenite (SS) supplementation at 0.3 mg/kg
Number of subjects: 1152
Study: 35124285

Group type: COMPARATOR
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Operative treatment (pronator teres rerouting, FCU transfer to ECRB, fractional lengthening)
Number of subjects: 19
Study: 33994125

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX every 14 days for up to 12 cycles
Number of subjects: 218

Group type: COMPARATOR
Intervention: Platinum‐etoposide (PE) every 21 days for 6–8 cycles
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 218

Group type: COMPARATOR
Intervention: Platinum‐etoposide (PE)
Number of subjects: 218
Study: 32304832

Group type: EXPERIMENTAL
Intervention: Ragweed SLIT-tablet (12 Amb a 1-Unit)
Number of subjects: 1025
Study: 36288831

Group type: EXPERIMENTAL
Intervention: Active tDCS (C3/Fp2 montage), 10 sessions over 2 weeks, monophasic continuous current, 2 mA for 20 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active tDCS (C3/Fp2 montage)
Number of subjects: 40
Study: 33561153

Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: High low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Elevated triglyceride
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Elevated total cholesterol
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein cholesterol (HDL-C)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Age above 64 years
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Age 40-64 years
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Walking <150 minutes per week
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Raised fasting blood glucose (FBG)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Medium socio-economic status
Number of subjects: 321
Study: 35738744

Group type: EXPERIMENTAL
Intervention: Biolimus-Coated Balloon (BCB)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Plain Balloon (Control)
Number of subjects: 212
Study: 32124032

Group type: EXPERIMENTAL
Intervention: Navigation technique
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intramedullary technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Extramedullary positioning
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intramedullary positioning
Number of subjects: 300

Group type: COMPARATOR
Intervention: Navigation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Navigation and Intramedullary groups
Number of subjects: 300
Study: 34847501

Group type: EXPERIMENTAL
Intervention: Risperidone ISM® 75 or 100 mg once-monthly intramuscular injections for 12 months
Number of subjects: 215
Study: 34411756

Group type: EXPERIMENTAL
Intervention: Conventional dark ink tattoos
Number of subjects: 34

Group type: COMPARATOR
Intervention: UV ink tattoos
Number of subjects: 34
Study: 34412109

Group type: EXPERIMENTAL
Intervention: THC + CBD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CBD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: THC
Number of subjects: 18
Study: 33023494

Group type: EXPERIMENTAL
Intervention: Thrombolysis implementation intervention
Number of subjects: 0
Study: 35509348

Group type: COMPARATOR
Intervention: gLiFE (group-based LiFE)
Number of subjects: 252

Group type: COMPARATOR
Intervention: LiFE (individually delivered LiFE)
Number of subjects: 252
Study: 34586227

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation with ranibizumab injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: Panretinal photocoagulation alone
Number of subjects: 30